Adma Biologics (ADMA) Long-Term Deferred Tax (2012 - 2025)
Adma Biologics (ADMA) posted Long-Term Deferred Tax of $73.3 million for Q4 2025, down 1.57% on a QoQ basis from $74.4 million in Q3 2025, and down 13.07% year-over-year from $84.3 million in Q4 2024.
Adma Biologics (ADMA) Long-Term Deferred Tax (2012 - 2025) Analysis & Trends
Adma Biologics' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $73.3 million for Q4 2025.
- Quarterly Long-Term Deferred Tax fell 13.07% year-over-year to $73.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.3 million (down 13.07% YoY) and the FY2025 annual result came in at $73.3 million, down 13.07% from the prior year.
- Long-Term Deferred Tax was $73.3 million for Q4 2025 at Adma Biologics, down from $74.4 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $84.3 million in Q4 2024 and bottomed at $73.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.26 Mn |
| Sep 30, 2025 | 74.43 Mn |
| Jun 30, 2025 | 79.24 Mn |
| Mar 31, 2025 | 80.86 Mn |
| Dec 31, 2024 | 84.28 Mn |
| Dec 31, 2018 | 624,610.00 |
| Dec 31, 2015 | 1.02 Mn |
| Mar 31, 2013 | 245,416.00 |
| Dec 31, 2012 | 363,403.00 |